Journal Home
Search for

Volume 65, Issue 10, Pages 887-892 (15 May 2009)


View previous. 18 of 22 View next.

Systemic Propranolol Acts Centrally to Reduce Conditioned Fear in Rats Without Impairing Extinction

Jose Rodriguez-Romaguerab, Francisco Sotres-Bayona, Devin MuelleraCorresponding Author Informationemail address, Gregory J. Quirka

Received 3 December 2008; received in revised form 4 January 2009; accepted 7 January 2009. published online 02 March 2009.

Background

Previous work has implicated noradrenergic β-receptors in the consolidation and reconsolidation of conditioned fear. Less is known, however, about their role in fear expression and extinction. The β-receptor blocker propranolol has been used clinically to reduce anxiety. With an auditory fear conditioning task in rats, we assessed the effects of systemic propranolol on the expression and extinction of two measures of conditioned fear: freezing and suppression of bar-pressing.

Methods

One day after receiving auditory fear conditioning, rats were injected with saline, propranolol, or peripheral β-receptor blocker sotalol (both 10 mg/kg, IP). Twenty minutes after injection, rats were given either 6 or 12 extinction trials and were tested for extinction retention the following day. The effect of propranolol on the firing rate of neurons in prelimbic (PL) prefrontal cortex was also assessed.

Results

Propranolol reduced freezing by more than 50%, an effect that was evident from the first extinction trial. Suppression was also significantly reduced. Despite this, propranolol had no effect on the acquisition or retention of extinction. Unlike propranolol, sotalol did not affect fear expression, although both drugs significantly reduced heart rate. This suggests that propranolol acts centrally to reduce fear. Consistent with this, propranolol reduced the firing rate of PL neurons.

Conclusion

Propranolol reduced the expression of conditioned fear, without interfering with extinction learning. Reduced fear with intact extinction suggests a possible use for propranolol in reducing anxiety during extinction-based exposure therapies, without interfering with long-term clinical response.

a Department of Psychiatry and Anatomy & Neurobiology, University of Puerto Rico, San Juan, Puerto Rico

b Department of Psychology Undergraduate Program, University of Puerto Rico, San Juan, Puerto Rico

Corresponding Author InformationAddress reprint requests to Devin Mueller, Ph.D., Department of Psychology, University of Wisconsin-Milwaukee, P.O. Box 413, Milwaukee, WI 53201

PII: S0006-3223(09)00034-1

doi:10.1016/j.biopsych.2009.01.009


View previous. 18 of 22 View next.